Cancer Available online: https://www.who.int/news-room/fact-sheets/detail/cancer.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/CAAC.21660.

Article  PubMed  Google Scholar 

Zhang Y, Zhang Z. The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications. Cell Mol Immunol. 2020;17:807–21. https://doi.org/10.1038/S41423-020-0488-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8:1069–86. https://doi.org/10.1158/2159-8290.CD-18-0367.

Article  PubMed  Google Scholar 

Walsh, R.J.; Soo, R.A. Resistance to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Biomarkers and Therapeutic Strategies. Ther Adv Med Oncol. 2020;12, https://doi.org/10.1177/1758835920937902.

Zhou F, Qiao M, Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2020;18:279–93. https://doi.org/10.1038/s41423-020-00577-5. 18:2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han Y, Liu D, Li L. PD-1/PD-L1 Pathway: Current Researches in Cancer. Am J Cancer Res. 2020;10:727–42.

CAS  PubMed  PubMed Central  Google Scholar 

Paik J. Nivolumab Plus Relatlimab: First Approval. Drugs. 2022;82:925–31. https://doi.org/10.1007/S40265-022-01723-1.

Article  CAS  PubMed  Google Scholar 

Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J, Meng L, Xin Y, Jiang X. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. Cell Biosci. 2023;13:1–23. https://doi.org/10.1186/S13578-023-01073-9. 13:1.

Article  PubMed  PubMed Central  Google Scholar 

Rousseau, A.; Parisi, C.; Barlesi, F. Anti-TIGIT Therapies for Solid Tumors: A Systematic Review. ESMO Open. 2023;8. https://doi.org/10.1016/J.ESMOOP.2023.101184.

Zou, W.; Wolchok, J.D.; Chen, L. PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers, and Combinations. Sci Transl Med. 2016;8. https://doi.org/10.1126/SCITRANSLMED.AAD7118.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med. 2012;366:2443–54. https://doi.org/10.1056/NEJMOA1200690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med. 2013;369:134–44. https://doi.org/10.1056/NEJMOA1305133.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan, S.; Zhan, Y.; Chen, X.; Wu, B.; Liu, B. Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors. Front Oncol. 2019;9. https://doi.org/10.3389/FONC.2019.01101.

Tang, Q.; Chen, Y.; Li, X.; Long, S.; Shi, Y.; Yu, Y.; Wu, W.; Han, L.; Wang, S. The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Front Immunol. 2022;13. https://doi.org/10.3389/FIMMU.2022.964442.

Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. 2020. https://doi.org/10.1146/annurev-pathol-042020.

Article  Google Scholar 

Li, S.; Na, R.; Li, X.; Zhang, Y.; Zheng, T. Targeting Interleukin-17 Enhances Tumor Response to Immune Checkpoint Inhibitors in Colorectal Cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2022;1877–188758. https://doi.org/10.1016/J.BBCAN.2022.188758.

Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597.

Article  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med. 2012;366:2455–65. https://doi.org/10.1056/nejmoa1200694.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kluger, H.M.; Tawbi, H.A.; Ascierto, M.L.; Bowden, M.; Callahan, M.K.; Cha, E.; Chen, H.X.; Drake, C.G.; Feltquate, D.M.; Ferris, R.L.; et al. Defining Tumor Resistance to PD-1 Pathway Blockade: Recommendations from the First Meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer. 2020;8. https://doi.org/10.1136/JITC-2019-000398.

Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune Checkpoint Inhibitors: Recent Progress and Potential Biomarkers. Exp Mol Med 2018;50.

Shindo Y, Hazama S, Tsunedomi R, Suzuki N, Nagano H. Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers (Basel). 2019;11. https://doi.org/10.3390/CANCERS11091223.

Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013;39:1–10. https://doi.org/10.1016/J.IMMUNI.2013.07.012.

Article  PubMed  Google Scholar 

Mellman I, Chen DS, Powles T, Turley SJ. The Cancer-Immunity Cycle: Indication, Genotype, and Immunotype. Immunity. 2023;56:2188–205. https://doi.org/10.1016/j.immuni.2023.09.011.

Article  CAS  PubMed  Google Scholar 

Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016;44:955. https://doi.org/10.1016/J.IMMUNI.2016.05.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Starzer, A.M.; Preusser, M.; Berghoff, A.S. Immune Escape Mechanisms and Therapeutic Approaches in Cancer: The Cancer-Immunity Cycle. Ther Adv Med Oncol. 2022;14. https://doi.org/10.1177/17588359221096219/ASSET/IMAGES/LARGE/10.1177_17588359221096219-FIG1.JPEG.

Fujiwara, Y.; Mittra, A.; Naqash, A.R.; Takebe, N. A Review of Mechanisms of Resistance to Immune Checkpoint Inhibitors and Potential Strategies for Therapy. Cancer Drug Resistance. 2020;3:252. https://doi.org/10.20517/CDR.2020.11.

Hou Y, Zhang R, Zong J, Wang W, Zhou M, Yan Z, Li T, Gan W, Lv S, Zeng Z, et al. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer. Front Immunol. 2022;13: 892512. https://doi.org/10.3389/FIMMU.2022.892512/BIBTEX.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao X, Subramanian S. Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. Cancer Res. 2017;77:817–22. https://doi.org/10.1158/0008-5472.

Article  PubMed  Google Scholar 

Rieth J, Subramanian S. Mechanisms of intrinsic tumor resistance to immunotherapy. Int J Mol Sci. 2018;19:1340. https://doi.org/10.3390/IJMS19051340.

Article  PubMed  PubMed Central  Google Scholar 

Kim TK, Herbst RS, Chen L. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol. 2018;39:624–31. https://doi.org/10.1016/j.it.2018.05.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52:17–35. https://doi.org/10.1016/J.IMMUNI.2019.12.011.

Article  CAS  PubMed  Google Scholar 

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade-Based Immunotherapy. Science. 2018;362. https://doi.org/10.1126/SCIENCE.AAR3593.

Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines. Cancer Immunol Res. 2013;1:11. https://doi.org/10.1158/2326-6066.CIR-13-0022.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. Cell. 2015;160:48–61. https://doi.org/10.1016/J.CELL.2014.12.033.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-Small Cell Lung Cancer. Science. 2015;348:124. https://doi.org/10.1126/SCIENCE.AAA1348.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. Cancer Exome Analysis Reveals a T-Cell-Dependent Mechanism of Cancer Immunoediting. Nature. 2012;482:400–4. https://doi.org/10.1038/NATURE10755.

Article  CAS  PubMed  PubMed Central